Current and Emerging Treatment Strategies for Graves’ Orbitopathy

Keyphrases

• Current Treatment 100%
• Treatment Strategy 100%
• Emerging Treatments 100%
• Graves' Orbitopathy 100%
• Graves' Disease 50%
• Glucocorticoid Therapy 16%
• Clinical Evaluation 16%
• Disease Severity 16%
• Disease Activity 16%
• Moderate to Severe 16%
• Patient Assessment 16%
• Cyclosporine 16%
• Severe Disease 16%
• Rituximab 16%
• Mycophenolate Mofetil 16%
• Lack of Response 16%
• Methotrexate 16%
• Treatment Paradigms 16%
• Ophthalmologist 16%
• Selenium 16%
• Biological Agents 16%
• Eye Diseases 16%
• Second-line Therapy 16%
• Novel Immunotherapy 16%
• Local Therapy 16%
• Mild Disease 16%
• Risk Factor Modification 16%
• Tocilizumab 16%
• New Biologics 16%
• Management Options 16%
• Treatment Implications 16%
• Thyroid Function Tests 16%
• Multispecialty Team 16%
• New Management 16%
• Intravenous Glucocorticoid Therapy 16%
• Teprotumumab 16%
• Orbital Radiotherapy 16%
• Orbitopathy 16%
• Endocrinologists 16%
• Autoimmune Thyroid Disease 16%

Medicine and Dentistry

• Endocrine Ophthalmopathy 100%
• Emerging Treatment 100%
• Diseases 66%
• Glucocorticoid 50%
• Graves' Disease 50%
• Clinical Trial 16%
• Disease Severity 16%
• Disease Activity 16%
• Immunotherapy 16%
• Cyclosporine 16%
• Rituximab 16%
• Local Therapy 16%
• Methotrexate 16%
• Eye Disease 16%
• Risk Factor Modification 16%
• Autoimmune Thyroiditis 16%
• Tocilizumab 16%
• Endocrinologist 16%
• Thyroid Function Test 16%
• Teprotumumab 16%
• Mycophenolate Mofetil 16%
• Radiation Therapy 16%
• Selenium 16%